Navigation Links
Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugai's Actemra for Rheumatoid Arthritis
Date:8/6/2008

However, Pharmacy Directors Disagree About Formulary Inclusion for Key Emerging Biologic Agents That Will Launch for the Disease in the Next Few

Years, According to a New Report from Decision Resources

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 89 percent of surveyed rheumatologists anticipate prescribing Roche/Chugai's Actemra, following the expected launch of the drug for rheumatoid arthritis in 2009. Surveyed rheumatologists indicated they would prescribe Actemra, an interleukin-6 inhibitor, to an estimated 10 percent of their patients six months after the drug's launch. On July 29, 2008, the Food and Drug Administration's Arthritis Advisory Committee recommended Actemra's approval for rheumatoid arthritis. Although some panel members expressed concern about data that suggested the potential for negative side effects, the committee indicated that clinical trials supported Actemra's efficacy.

The new Physician & Payer Forum report, Biologics in Rheumatoid Arthritis: Physician and Payer Perspective on Recently Launched and Emerging Biologics in Rheumatoid Arthritis, finds that rheumatologists are highly receptive to the many new agents expected to launch by 2011, but they may face increasing barriers to reimbursement and limited access to novel biological agents.

In addition to Actemra, the other emerging biologic agents included in the report survey are UCB's Cimzia, Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Biogen Idec/Genentech/Roche's ocrelizumab. The report finds that managed care organizations' (MCO) pharmacy directors disagree on the likelihood of formulary inclusion for key emerging biologics as their expectations varied widely in response to whether they will include these agents on their formularies. Pharmacy directors may be reserving judgment on key biologic agents until more clinical data becomes available.

Nevertheless, surveyed rheumatologists remain steadfast in their preference for TNF-alpha inhibitors over other biologic agents for the treatment of rheumatoid arthritis. Ninety-nine of 100 surveyed rheumatologists reported prescribing TNF-alpha inhibitors as first-line biologic therapy for the disease.

"Most rheumatologists expect the dominance of TNF-alpha inhibitors to continue, and possibly expand, over the next two years," said Cindy Mundy, Ph.D., director at Decision Resources. "The upcoming launches of Cimzia and golimumab will increase the number of TNF-alpha inhibitors approved for rheumatoid arthritis from three to five. Following the launches of Cimzia and golimumab, nearly half of surveyed rheumatologists expect to prescribe three or more TNF-alpha inhibitors before moving to a different class of agents."

Biologics in Rheumatoid Arthritis: Physician and Payer Perspective on Recently Launched and Emerging Biologics in Rheumatoid Arthritis is based on a U.S. survey of 100 rheumatologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
2. Mothers from affluent neighborhoods near highways increase odds of low weight babies by 81 percent
3. A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market
4. Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance
5. Galderma announces approval for Differin gel 0.1 percent in Japan
6. 89 percent of childrens food products provide poor nutritional quality
7. Statement on CDC Announcement That 70 Percent of the U. S. Population Now Receives Optimally Fluoridated Water By Mark J. Feldman, DMD, President, American Dental Association
8. Cadaver tissue fails nearly 25 percent of the time in young ACL reconstructions
9. Primary Care Physicians Prescriptions of Aricept for Alzheimers Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008
10. Disaboom Survey Reveals 52 Percent of Americans Would Rather be Dead Than Disabled
11. Economist Finds Highmark/IBC Merger Would Result in 70 Percent Share in Pennsylvania, Far Higher Than Initial Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in the health care ... leaders in the nursing and health care industry. It also provides insight to the ... University. , As the nursing industry is coming out of one of the ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of certified ... industries. Aside from its GMP accreditation, Validation Center is also a registered authority ... services and staff. , Validation Center is ISO17025 accredited and only offers its ...
(Date:5/26/2016)... ... 2016 , ... There are many ways to cook a hot dog, but ... Americans prefer their dogs straight off the grill. Of the 90 percent of Americans ... to cook a hot dog, far outpacing other cooking methods such as steaming (12 ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... May 25, 2016 Digital Health Dialog, ... it by the US Patent and Trademark Office ... includes proprietary processes for electronic opt-­in and processing ... wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for individuals ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
Breaking Medicine Technology: